NCT00771927View on ClinicalTrials.gov

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures

CompletedOBSERVATIONAL

Enrollment

1,005

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Epilepsies, Partial

Interventions

DRUG

Lacosamide

Vimpat was used as per site routine practices, and in-line with the marketing authorization.

Trial Locations (62)

Unknown

Bron

Dijon

La Tronche

Montpellier

Nantes

Paris

Saint-Brieuc

Tain-l'Hermitage

Aschaffenburg

Bad Berka

Berlin

Bernau

Bielefeld

Bonn

Dresden

Düsseldorf

Erlangen

Essen

Freiburg im Breisgau

Göttingen

Halle

Hamburg

Jena

Kehl-Kork

Kiel

Koningstein-Falkenstein

Krefeld

Mainz

Marburg

München

Münster

Neuburg am Inn

Neukirchen-Vluyn

Oldenburg

Osnabrück

Potsdam

Radeberg, Sachsen

Ravensburg

Rotenburg (Wümme)

Stuttgart

Ulm

Vogtareuth

Westerstede

Blaricum

Heeze

Nijmegen

Barcelona

El Vendrell

Plymouth

Fulwood, Preston

Bangor

Birmingham

Cardiff

Dundee

Edinburgh

Leeds

Leicester

London

Middlesbrough

Salford

Sheffield

Stoke-on-Trent

Sponsors

Lead Sponsor

All Listed Sponsors

lead

UCB Pharma

INDUSTRY

NCT00771927 - Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures | Biotech Hunter | Biotech Hunter